Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year.
The post Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test appeared first on MedCity News.
